Enzyme/ROS dual-sensitive nanoplatform with on-demand Celastrol release capacity for enhanced ulcerative colitis therapy by ROS scavenging, microbiota rebalancing, inflammation alleviating
Authors:
Open Access
- 26 July 2024
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-18
Abstract
Background: The oral administration of drugs for treating ulcerative colitis (UC) is hindered by several factors, including inadequate gastrointestinal stability, insufficient accumulation in colonic lesions, and uncontrolled drug release. Methods: A multiple sensitive nano-delivery system comprising β-cyclodextrin (CD) and 4-(hydroxymethyl)phenylboronic acid (PAPE) with enzyme/reactive oxygen species (ROS) sensitivity was developed to load celastrol (Cel) as a comprehensive treatment for UC. Results: Owing to the positive charge in the site of inflamed colonic mucosa, the negatively charged nanomedicine (Cel/NPs) could efficiently accumulate. Expectedly, Cel/NPs showed excellent localization ability to colon in vitro and in vivo tests. The elevated concentration of ROS and intestinal enzymes in the colon microenvironment quickly break the CD, resulting in Cel release partially to rebalance microbiota and recover the intestinal barrier. The accompanying cellular internalization of residual Cel/NPs, along with the high concentration of cellular ROS to trigger Cel burst release, could decrease the expression of inflammatory cytokines, inhibit colonic cell apoptosis, promote the macrophage polarization, scavenge ROS, and regulate the TLR4/NF-κB signaling pathway, which certified that Cel/NPs possessed a notably anti-UC therapy outcome. Conclusions: We provide a promising strategy for addressing UC symptoms via an enzyme/ROS-sensitive oral platform capable of releasing drugs on demand. GraphicalKeywords
Funding Information
- National Natural Science Foundation of China (82304731)
- Natural Science Foundation of Sichuan Province (2023NSFSC1784)
- Foundation of Chengdu Medical College (CYZZD21-02)
- Disciplinary Construction Innovation Team Foundation of Chengdu Medical College (CMC-XK-2104)
- Key Research and Development Program of Sichuan Province (2020YFN0028)
This publication has 45 references indexed in Scilit:
- An oral polyphenol host-guest nanoparticle for targeted therapy of inflammatory bowel diseaseActa Biomaterialia, 2023
- Oral Delivery of Transformable Bilirubin Self‐Assembled System for Targeted Therapy of ColitisAdvanced Healthcare Materials, 2023
- Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategiesBiomedicine & Pharmacotherapy, 2023
- Hyaluronic acid modified oral drug delivery system with mucoadhesiveness and macrophage-targeting for colitis treatmentCarbohydrate Polymers, 2023
- Cyclodextrins applied to the treatment of lysosomal storage disordersAdvanced Drug Delivery Reviews, 2022
- A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitisActa Pharmaceutica Sinica B, 2022
- Genetically engineered pH-responsive silk sericin nanospheres with efficient therapeutic effect on ulcerative colitisActa Biomaterialia, 2022
- Glycogen-based pH and redox sensitive nanoparticles with ginsenoside Rh2 for effective treatment of ulcerative colitisBiomaterials, 2022
- Calcium pectinate and hyaluronic acid modified lactoferrin nanoparticles loaded rhein with dual-targeting for ulcerative colitis treatmentCarbohydrate Polymers, 2021
- Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasisChemico-Biological Interactions, 2014